Analysts Update Ratings on Biogen Amid Institutional Buying
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Bank of America updated its price objective and rating for Biogen shares. Citigroup reissued a neutral rating on Biogen. Separately, reports indicate that several institutional investors recently acquired new stakes in Biogen, including BlackRock and Saudi Central Bank.
From tickerreport.com
Why it matters
Analyst ratings and institutional investment activity directly influence Biogen's stock valuation. The recent buying activity by large funds suggests continued interest in the biotechnology company.
From tickerreport.com
Who's involved
- Bank of AmericaUpdated its price objective and rating for Biogen shares.
- BiogenThe biotechnology company whose shares are being rated and bought.
- CitigroupReissued a neutral rating on Biogen shares.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- BiogenSpeculative
Could see its stock valuation change due to analyst rating changes and institutional investment activity.
Keep exploring
The entities involved
-
Bank of America
American multinational banking and financial services corporation
-
Biogen
American multinational biotechnology company
Nothing else this week.
-
Citigroup
American investment bank and financial services corporation
Related events
- Citigroup upped its price objective and gave a 'buy' rating, while Royal Bank of Canada reissued an 'outperform' rating for Abbott Laboratories.
- Citigroup reissued a buy rating on Bankinter.
- Citigroup reiterated a neutral rating on Norfolk Southern stock, while JPMorgan Chase & Co. issued a price target report.
- Bank of America, Citigroup, and Royal Bank of Canada issued rating upgrades and price target increases for International Paper.
- Citigroup and Jefferies Financial Group raised their price targets and issued buy ratings for Beauty.